Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?

Curr Oncol · 2025 · PMC12731412 · PMID 41440220

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the final prespecified analysis, the median OS was 42.1 months for the olaparib plus abiraterone arm compared to 34.7 months for the placebo plus abiraterone arm (HR 0.81), a difference that did not reach statistical significance [ 47 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.